Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909172 | 0.90 | MAPT (0.49) | PTPN1MAPTTP53RXFP1KCNH2 | |
| SCHEMBL5263131 | 0.80 | HPGD (0.52) | MAPTALDH1A1HPGDMAPKAPK2 | |
| SCHEMBL29717252 | 0.79 | TOP2A (0.56) | — | |
| SCHEMBL11457930 | 0.74 | MEN1 (0.61) | PTPN1MAPTTP53RXFP1KDM4E | |
| SCHEMBL5504372 | 0.73 | PTPN1 (0.76) | PTPN1MAPTTP53RXFP1KDM4E | |
| SCHEMBL4903739 | 0.73 | SCN10A (0.51) | — | |
| SCHEMBL5508682 | 0.73 | PTPN1 (0.67) | PTPN1MAPTTP53RXFP1KDM4E | |
| SCHEMBL4901768 | 0.72 | DAO (0.46) | — | |
| SCHEMBL4908579 | 0.72 | KMO (0.48) | — | |
| SCHEMBL4909723 | 0.72 | TOP2A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | claimed |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | PTPN1 2483/4885MAPT 2515/4885TP53 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.